首页工具

T-2307

产品编号 T40994 CAS 873546-31-7

T-2307, a broad-spectrum arylamidine compound, demonstrates potent antifungal properties both in vitro and in vivo. Its activity extends to clinically significant pathogens such as Candida species (MIC range: 0.00025 to 0.0078 μg/ml), Cryptococcus neoformans (MIC range: 0.0039 to 0.0625 μg/ml), and Aspergillus species (MIC range: 0.0156 to 4 μg/mL).

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

T-2307, CAS 873546-31-7

规格	价格/CNY		货期	数量
2 mg	￥ 2,890		5日内发货

大包装超大折扣，点击咨询

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

产品描述	T-2307, a broad-spectrum arylamidine compound, demonstrates potent antifungal properties both in vitro and in vivo. Its activity extends to clinically significant pathogens such as Candida species (MIC range: 0.00025 to 0.0078 μg/ml), Cryptococcus neoformans (MIC range: 0.0039 to 0.0625 μg/ml), and Aspergillus species (MIC range: 0.0156 to 4 μg/mL).
体外活性	T-2307 exhibits potent activity against fluconazole-resistant and fluconazole-susceptible-dose-dependent Candida albicans strains as well as against azole-susceptible strains[1]. T-2307 shows efficacy in a murine model of candida glabrata infection despite?in vitro?trailing growth phenomena[2]. Cell Viability Assay[2]Cell Line: C. glabrata ATCC 90030 Concentration: 0.000125, 0.00025, 0.0005, 0.001, 0.002, 0.0039, 0.0078, 0.0156, 0.0313, 0.0625, 0.125 μg/mL Incubation Time: 24 and 48 hours Result: C. glabrata exhibited significant trailing growth at concentrations between 0.0039 and 0.125 μg/mL at 48 h. The trailing growth of C. glabrata at 24 h of incubation was similar to that at 48 h.
体内活性	In mouse models of disseminated candidiasis, cryptococcosis, and aspergillosis, the ED 50 of T-2307 were 0.00755, 0.117, and 0.391 mg/kg, respectively[1]. Animal Model: 4-week-old specific-pathogen-free ICR strain male mice bearing systemic infections with Candida albicans , Cryptococcus neoformans , and Aspergillus fumigatus[1]. Dosage: 0.001, 0.1, 1 mg/kg Administration: Subcutaneously administered; once a day for 7 days, beginning at 2 h after the infection. Result: In the systemic infection caused by Candida albicans , all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 0.01 mg/kg?compared with that in the control mice. The calculated ED 50 s of T-2307were 0.00755 mg/kg. In the systemic infection caused by Cryptococcus neoformans , all the control mice died by day 9. Mortality was significantly delayed in mice administered T-2307 at a dose of 0.1 mg/kg?compared with that in the control mice. The calculated ED 50 s of T-2307 were 0.117 mg/kg. In the systemic infection caused by Aspergillus fumigatus , all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 1 mg/kg compared with that in the control mice. The calculated ED 50 s of T-2307 were 0.391 mg/kg.

分子量	437.5777
分子式	C25H35N5O2
CAS No.	873546-31-7

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Junichi Mitsuyama, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008 Apr;52(4):1318-24. 2. Eio Yamada, et al. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother. 2010 Sep;54(9):3630-4.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +